NCT00207090View on ClinicalTrials.gov

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Advanced Solid TumorsNeoplasms
Interventions
DRUG

ixabepilone

ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression

DRUG

Rifampin

rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2

Trial Locations (1)

44195

The Cleveland Clinic Foundation, Cleveland

Sponsors

Lead Sponsor

R-Pharm
All Listed Sponsors
lead

R-Pharm

INDUSTRY